{"id":3003,"date":"2018-08-17T16:48:26","date_gmt":"2018-08-17T11:18:26","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3003"},"modified":"2021-07-24T12:57:02","modified_gmt":"2021-07-24T07:27:02","slug":"clinical","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/clinical","title":{"rendered":"KEY CLINICAL OUTCOMES"},"content":{"rendered":"

Bexion Pharmaceuticals\u2019 Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomas<\/strong><\/p>\n

Bexion Pharmaceuticals\u2019 investigational cancer treatment, BXQ-350, is receiving\u00a0lots of mainstream media coverage\u00a0as a potential game-changer.<\/p>\n

BXQ-350 is a formulation of a synthetically produced, human lysosomal protein, Saposin C (sphingolipid activator protein, or SapC), and the phospholipid dioleoylphosphatidylserine (DOPS). It is being developed as a first-in-class treatment for solid tumors and gliomas.<\/p>\n

In animal models, the effect of BXQ-350 has been significant. Earlier this year at the American Society for Clinical Oncology<\/a>, Bexion unveiled\u00a0preliminary data of a Phase Ia trial\u00a0in a poster presentation that revealed some promising results. Of the 17 patients, nine with Glioblastoma Multiforme and eight with other solid tumors, the company saw a positive response in seven patients after 113 days. One patient with appendiceal carcinoma saw a partial response and six patients showed signs of disease stability. Of those six, one was a high-grade glioma patient who showed stable disease signs for greater than 19 months.<\/p>\n

BeiGene Initiates Phase III Pivotal Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer in China<\/strong><\/p>\n

BeiGene announced that the first patient was dosed in a Phase III clinical trial of tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy, as a potential first-line treatment in Chinese patients with Stage IIIB or IV non-squamous non-small cell lung cancer (NSCLC).<\/p>\n

Tislelizumab is also being studied in global Phase III trials in solid tumors, including second-line non-small cell lung cancer, first-line hepatocellular carcinoma, and second-line esophageal squamous cell carcinoma; two global Phase II trials in previously treated advanced hepatocellular carcinoma and relapsed\/refractory mature T- and natural killer-cell lymphomas; and two pivotal Phase II trials in China in relapsed\/refractory classical Hodgkin\u2019s lymphoma and second-line urothelial cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"

Bexion Pharmaceuticals\u2019 Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomas Bexion Pharmaceuticals\u2019 investigational cancer treatment, BXQ-350, is receiving\u00a0lots of mainstream media coverage\u00a0as a potential game-changer. BXQ-350 is a formulation of a synthetically produced, human lysosomal protein, Saposin C (sphingolipid activator protein, or SapC), and the phospholipid dioleoylphosphatidylserine […]<\/p>\n","protected":false},"author":1,"featured_media":2785,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17485,17652,16690,17569,6733],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-3003","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-beigene","tag-bexion-pharmaceuticals","tag-glioblastoma-multiforme","tag-glioma","tag-non-small-cell-lung-cancer","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nKey KEY CLINICAL OUTCOMES Outcomes - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Bexion Pharmaceuticals\u2019 Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomasBexion Pharmaceuticals\u2019\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/clinical\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Key KEY CLINICAL OUTCOMES Outcomes - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Bexion Pharmaceuticals\u2019 Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomasBexion Pharmaceuticals\u2019\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/clinical\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-17T11:18:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09021351\/Pharma-research.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1026\" \/>\n\t<meta property=\"og:image:height\" content=\"486\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Key KEY CLINICAL OUTCOMES Outcomes - DelveInsight Business Research","description":"Bexion Pharmaceuticals\u2019 Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomasBexion Pharmaceuticals\u2019","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/clinical","og_locale":"en_US","og_type":"article","og_title":"Key KEY CLINICAL OUTCOMES Outcomes - DelveInsight Business Research","og_description":"Bexion Pharmaceuticals\u2019 Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomasBexion Pharmaceuticals\u2019","og_url":"https:\/\/www.delveinsight.com\/blog\/clinical","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-08-17T11:18:26+00:00","article_modified_time":"2021-07-24T07:27:02+00:00","og_image":[{"width":1026,"height":486,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09021351\/Pharma-research.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/clinical","url":"https:\/\/www.delveinsight.com\/blog\/clinical","name":"Key KEY CLINICAL OUTCOMES Outcomes - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/clinical#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/clinical#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09021351\/Pharma-research.jpg","datePublished":"2018-08-17T11:18:26+00:00","dateModified":"2021-07-24T07:27:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Bexion Pharmaceuticals\u2019 Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomasBexion Pharmaceuticals\u2019","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/clinical"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/clinical#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09021351\/Pharma-research.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09021351\/Pharma-research.jpg","width":1026,"height":486,"caption":"cancer"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09021351\/Pharma-research-300x142.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BeiGene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bexion Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Glioblastoma multiforme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Glioma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BeiGene<\/span>","<span class=\"advgb-post-tax-term\">Bexion Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Glioblastoma multiforme<\/span>","<span class=\"advgb-post-tax-term\">Glioma<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 17, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 17, 2018 4:48 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3003"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3003\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2785"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3003"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3003"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}